NI201500063A - Tratamiento de cáncer con pomalidomida en un individuo con daño renal - Google Patents

Tratamiento de cáncer con pomalidomida en un individuo con daño renal

Info

Publication number
NI201500063A
NI201500063A NI201500063A NI201500063A NI201500063A NI 201500063 A NI201500063 A NI 201500063A NI 201500063 A NI201500063 A NI 201500063A NI 201500063 A NI201500063 A NI 201500063A NI 201500063 A NI201500063 A NI 201500063A
Authority
NI
Nicaragua
Prior art keywords
individual
pomalidomide
kidney damage
cancer treatment
cancer
Prior art date
Application number
NI201500063A
Other languages
English (en)
Spanish (es)
Inventor
Eve Kasserra Claudia
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of NI201500063A publication Critical patent/NI201500063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NI201500063A 2012-11-05 2015-05-04 Tratamiento de cáncer con pomalidomida en un individuo con daño renal NI201500063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722722P 2012-11-05 2012-11-05
US201361764466P 2013-02-13 2013-02-13

Publications (1)

Publication Number Publication Date
NI201500063A true NI201500063A (es) 2015-09-10

Family

ID=50628132

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500063A NI201500063A (es) 2012-11-05 2015-05-04 Tratamiento de cáncer con pomalidomida en un individuo con daño renal

Country Status (15)

Country Link
US (1) US20150297579A1 (enExample)
EP (1) EP2914112A4 (enExample)
JP (1) JP2015535291A (enExample)
CN (1) CN104902754A (enExample)
AU (1) AU2013337352A1 (enExample)
BR (1) BR112015010039A2 (enExample)
CA (1) CA2889987A1 (enExample)
EA (1) EA201590883A1 (enExample)
HK (1) HK1214552A1 (enExample)
IL (1) IL238563A0 (enExample)
MX (1) MX2015005548A (enExample)
NI (1) NI201500063A (enExample)
PH (1) PH12015501002A1 (enExample)
SG (1) SG11201503456TA (enExample)
WO (1) WO2014071280A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507759WA (en) * 2013-04-02 2015-10-29 Celgene Corp Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
WO2019051125A1 (en) 2017-09-06 2019-03-14 Translational Drug Development, Llc AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS AND METHODS FOR INHIBITING HISTONE DEACETYLASE
EP3297674B1 (en) * 2015-05-22 2023-01-04 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
CN105456232A (zh) * 2015-09-08 2016-04-06 刘剑 一种泊马度胺速溶膜剂及其制备方法
AU2016394945A1 (en) * 2016-03-02 2018-10-11 Translational Drug Development Llc Aminobenzimidazole derivatives
WO2018013689A1 (en) * 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
CN108721304B (zh) * 2017-04-17 2020-10-16 北京大学 用于治疗肿瘤的药物组合物及其用途
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
GB202012160D0 (en) * 2020-08-05 2020-09-16 Vicore Pharma Ab New compositions
EP4479082A2 (en) * 2022-02-15 2024-12-25 The Broad Institute, Inc. Cell-type specific targeting contractile injection system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP5339588B2 (ja) * 2008-11-10 2013-11-13 国立大学法人 新潟大学 サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬
JP5553275B2 (ja) * 2010-03-31 2014-07-16 国立大学法人金沢大学 金属錯体およびこれを有効成分として含有する抗がん剤
JP2014517915A (ja) * 2011-04-18 2014-07-24 セルジーン コーポレイション 多発性骨髄腫治療のためのバイオマーカー
EP3096142A3 (en) * 2011-04-29 2017-03-08 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Also Published As

Publication number Publication date
PH12015501002A1 (en) 2015-07-27
HK1214552A1 (zh) 2016-07-29
SG11201503456TA (en) 2015-05-28
WO2014071280A1 (en) 2014-05-08
JP2015535291A (ja) 2015-12-10
EA201590883A1 (ru) 2015-09-30
BR112015010039A2 (pt) 2017-07-11
US20150297579A1 (en) 2015-10-22
CA2889987A1 (en) 2014-05-08
EP2914112A4 (en) 2016-06-15
AU2013337352A1 (en) 2015-05-21
CN104902754A (zh) 2015-09-09
IL238563A0 (en) 2015-06-30
MX2015005548A (es) 2016-01-15
EP2914112A1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
NI201400073A (es) Compuestos terapéuticamente activos y sus método
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
MX2015015228A (es) Sobetirome en el tratamiento de enfermedades de mielinizacion.
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
MX2017007973A (es) Tratamiento de penfigo.
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX2016005294A (es) Metodos para tratar y prevenir enfermedad injerto contra huésped.
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX376937B (es) Metodos para tratar cancer pancreático mediante el uso de terapias de combinacion que comprenden irinotecano liposómico.
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
AR087918A1 (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
NI201400110A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
MX2018006613A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
ECSP14013195A (es) Catéter, en particular catéter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la próstata.
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario